Black Hawk Acquisition (BKHA) vs BioStem Technologies (BSEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($47.9 million vs $46.1 million), about 1.0 times the size. On valuation, BioStem Technologies trades at a lower trailing P/E (2.8x vs 34.9x for Black Hawk Acquisition).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | BSEM |
|---|---|---|
| Share price | $11.53 | $2.47 |
| Market cap | $47.89M | $46.12M |
| 1-day change | -6.49% | -6.44% |
| YTD return | — | -30.71% |
| 1-year return | — | -45.00% |
| 5-year return | — | +88.57% |
| P/E ratio (TTM) | 34.94 | 2.81 |
| Forward P/E | — | 8.52 |
| EPS (TTM) | $0.33 | $0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.15 | $8.40 |
| 52-week low | $11.00 | $2.25 |
| Distance from 52-week high | -12.32% | -70.60% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +183.40% |
| Average volume | 5.83K | 124.14K |
| Shares outstanding | 4.15M | 18.67M |
| Employees | — | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Black Hawk Acquisition trades at a higher earnings multiple (34.9x vs 2.8x trailing P/E).
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
BKHA vs BSEM FAQ
Which is bigger, Black Hawk Acquisition or BioStem Technologies?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $47.89M compared with $46.12M for BioStem Technologies (BSEM).
Which has the lower P/E ratio, BKHA or BSEM?
BSEM has the lower trailing P/E at 2.8, versus 34.9 for BKHA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Black Hawk Acquisition and BioStem Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.